Business Development


Kalyra Pharmaceuticals is applying it’s proprietary chemistry platform of bioisostere substitution to develop novel small molecules with enhanced potency, bioavailability and solubility. Kalyra’s focus is to develop a robust pipeline in the areas of analgesia, antibiotics, fibrosis and oncology.

Kalyra’s business strategy is to establish collaborative pharmaceutical partnerships to drive these new chemical entities through development and commercialization to address unmet medical needs.

For further information please contact: